Market Research Logo

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

Summary

Heart failure (HF) is a universal condition affecting people of all ages, but which is found most frequently in those over the age of 65 years. Although HF is manageable and significant breakthroughs in the treatment of chronic HF have been made in the past few decades, the condition still carries a poorer prognosis and quality of life than certain types of cancers. Moreover, the prevalence of HF is on the rise due to the aging global population; the increased prevalence of diabetes, obesity, and hypertension; and improved treatment and survival after myocardial infarction (MI).

It is estimated that the sales of HF therapeutics to be approximately US$3.7B across the 7MM in 2016. By 2026, the HF market expects to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of US$16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026. Novartis’ Entresto will be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of US$8.6B in 2022.

Major drivers of HF market growth over the forecast period are the -

  • Launch of Novartis’ first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), Entresto, in the US in 2015, 5EU in 2016, and Japan in 2020, significantly boosting market growth.
  • Launch of several chronic HF add-on therapies, including Amgen and Cytokinetics’ omecamtiv mecarbil.
  • Increase in the global prevalence of chronic HF and in the incidence of acute HF.
The 7MM chronic HF market size in 2016 was US$3.6B, and is expected to increase to US$15.6B by 2026 at a CAGR of 16.1%. The US was the largest market for chronic HF therapies, contributing 73.4% of total sales in the base year.

The report PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 provides a detailed analysis of the current HF market and indicates how it will evolve over the next decade following the launch of several new therapies. Moreover, it also highlights the major unmet needs in the HF space and provides strategic insights into how drug developers can target these lucrative opportunities.

Specifically, this report enables the following -
  • Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Amgen, Bayer, BMS, Cardiorentis, Cytokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Ono Pharmaceuticals, Pfizer.

Scope
  • Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM HF therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Heart Failure: Executive Summary
2.1 The HF Market Will Exhibit Strong Growth Between 2016 and 2026
2.2 Label Expansion to HF with Preserved Ejection Fraction Will Fuel Market Growth
2.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
2.4 Opportunities Remain for All Aspects of HF, But What the Market Really Needs Is a Transformational Therapy
2.5 Entresto Will Dominate the HF Market
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.1.3 Biomarkers/Targets of Interest
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast assumptions and methods
5.4.3 Diagnosed Incident Cases of HF by EF
5.4.4 Diagnosed Incident Cases of HF by Ventricular Dysfunction
5.4.5 Acute HF Hospitalizations
5.4.6 Hospital Length of Stay for Acute HF Hospitalization
5.4.7 Diagnosed Prevalent Cases of CHF
5.4.8 Diagnosed Prevalent Cases of CHF by EF
5.4.9 Diagnosed Prevalent Cases of CHF by NYHA Classes
5.5 Epidemiological Forecast for Heart Failure (2016-2026)
5.5.1 Diagnosed Incident Cases of HF
5.5.2 Age-Specific Diagnosed Incident Cases of HF
5.5.3 Sex-Specific Diagnosed Incident Cases of HF
5.5.4 Diagnosed Incident Cases of HF by EF
5.5.5 Diagnosed Incident Cases of HF by VD
5.5.6 Acute HF Hospitalizations
5.5.7 Hospital Length of Stay for Acute HF Hospitalization
5.5.8 Diagnosed Prevalent Cases of CHF
5.5.9 Age-Specific Diagnosed Prevalent Cases of CHF
5.5.10 Sex-Specific Diagnosed Prevalent Cases of CHF
5.5.11 Diagnosed Prevalent Cases of CHF by EF
5.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines and Leading Prescribed Drugs
6.2.2 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan
7 Competitive Assessment
7.1 Overview
7.2 Angiotensin-Converting Enzyme Inhibitors
7.2.1 Overview
7.2.2 Efficacy
7.2.3 Safety
7.2.4 Forecast
7.3 Angiotensin Receptor Blockers
7.3.1 Overview
7.3.2 Efficacy
7.3.3 Safety
7.3.4 Forecast
7.4 Entresto (Sacubitril + Valsartan)
7.4.1 Overview
7.4.2 Efficacy
7.4.3 Safety
7.4.4 SWOT Analysis
7.4.5 Forecast
7.5 Diuretics
7.5.1 Overview
7.5.2 Efficacy
7.5.3 Safety
7.5.4 Forecast
7.6 Beta Blockers
7.6.1 Overview
7.6.2 Efficacy
7.6.3 Safety
7.6.4 Forecast
7.7 Procoralan (Ivabradine)
7.7.1 Overview
7.7.2 Efficacy
7.7.3 Safety
7.7.4 SWOT Analysis
7.7.5 Forecast
7.8 Mineralocorticoid Receptor Antagonists
7.8.1 Overview
7.8.2 Efficacy
7.8.3 Safety
7.8.4 Forecast
7.9 Digoxin
7.9.1 Overview
7.9.2 Efficacy
7.9.3 Safety
7.9.4 Forecast
7.10 Pharmacological Therapies for Acute HF
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Therapies for HF-PEF Patients
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Lack of Therapies for Acute HF
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Lack of Therapies for Patients with Renal Impairment
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Preventative Therapies for Patients at Risk of Developing HF
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Use of Optimal Doses of HF Therapies
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
8.7 Patient Compliance
8.7.1 Unmet Need
8.7.2 Gap Analysis
8.7.3 Opportunity
8.8 Early Detection and Treatment of Patients with Worsening Chronic HF
8.8.1 Unmet Need
8.8.2 Gap Analysis
8.8.3 Opportunity
8.9 Dynamic Management of Patients with HF
8.9.1 Unmet Need
8.9.2 Gap Analysis
8.9.3 Opportunity
8.10 Options for Advanced HF Patients Who Are Unable to Receive a Heart Transplant
8.10.1 Unmet Need
8.10.2 Gap Analysis
8.10.3 Opportunity
8.11 Better Risk Stratification of Patients Admitted to the ED with Acute HF and Enhanced Outpatient Care
8.11.1 Unmet Need
8.11.2 Gap Analysis
8.11.3 Opportunity
9 Pipeline Assessment
9.1 Overview
9.2 Drugs in Clinical Development
9.2.1 Pipeline Drugs by Patient Population
9.3 Promising Drugs in Clinical Development
9.4 Omecamtiv Mecarbil
9.4.1 Overview
9.4.2 Efficacy
9.4.3 Safety
9.4.4 Dosing and Formulation
9.4.5 Potential Clinical and Commercial Positioning
9.4.6 SWOT Analysis
9.4.7 Forecast
9.5 Vericiguat
9.5.1 Overview
9.5.2 Efficacy
9.5.3 Safety
9.5.4 Dosing and Formulation
9.5.5 Potential Clinical and Commercial Positioning
9.5.6 SWOT Analysis
9.5.7 Forecast
9.6 RT-100
9.6.1 Overview
9.6.2 Efficacy
9.6.3 Safety
9.6.4 Dosing and Formulation
9.6.5 Potential Clinical and Commercial Positioning
9.6.6 SWOT Analysis
9.6.7 Forecast
9.7 CXL-1427
9.7.1 Overview
9.7.2 Efficacy
9.7.3 Safety
9.7.4 Dosing and Formulation
9.7.5 Potential Clinical and Commercial Positioning
9.7.6 SWOT Analysis
9.7.7 Forecast
9.8 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Amgen and Cytokinetics
10.3.1 Overview
10.3.2 Portfolio Assessment
10.4 Bayer (and Merck & Co.)
10.4.1 Overview
10.4.2 Portfolio Assessment
10.5 Bristol-Myers Squibb
10.5.1 Overview
10.5.2 Portfolio Assessment
10.6 Les Laboratoires Servier
10.6.1 Overview
10.6.2 Portfolio Assessment
10.7 Novartis
10.7.1 Overview
10.7.2 Portfolio Assessment
10.8 Renova Therapeutics
10.8.1 Overview
10.8.2 Portfolio Assessment
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Prevalent Chronic HF
12.3.3 Diagnosed Incidence of Acute HF
12.3.4 Percent Drug-Treated Patients
12.3.5 Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction
12.3.6 Drugs Included in Each Therapeutic Class
12.3.7 Launch and Patent Expiry Dates
12.3.8 General Pricing Assumptions
12.3.9 Individual Drug Assumptions
12.3.10 Generic Erosion
12.3.11 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for this Report
12.5 Primary Research - Payers Included in this Study
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analyst
12.7.2 Therapy Area Director
12.7.3 Epidemiologist
12.7.4 Managing Epidemiologists
12.7.5 Global Director of Therapy Analysis and Epidemiology
12.7.6 Global Head and EVP of Healthcare Operations and Strategy
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer
1.1 List of Tables
Table 1: Heart Failure: Key Metrics in the 7MM
Table 2: Types of Chronic HF
Table 3: The leading causes, as well as other less common causes, of HF.
Table 4: The compensatory mechanisms that are activated in a patient with HF.
Table 5: Key Diagnostic and prognostic biomarkers in HF.
Table 6: Overview of Clinically Relevant Biomarkers in HF
Table 7: shows a comparison of these two HF classification systems.
Table 8: Symptoms of Heart Failure
Table 9: Risk Factors and Comorbidities for HF
Table 10: NYHA Functional Classification for CHF (Classes I-IV).
Table 11: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016-2026
Table 12: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016-2026
Table 13: lists the common factors that precipitate acute HF.
Table 14: HF Treatment guidelines most commonly adhered to by physicians in the 7MM.
Table 15: summarizes the chronic HF-REF medications and drug classes most commonly used in the US, 5EU, and Japan, based on GlobalData’s primary and secondary research.
Table 16: Country Profile - US
Table 17: Country Profile - 5EU
Table 18: Country Profile - Japan
Table 19: Summary of major clinical trials assessing the efficacy of ACE inhibitors in HF-REF patients.
Table 20: Summary of major clinical trials assessing the efficacy of ARBs in HF-REF patients.
Table 21: Product Profile - Entresto
Table 22: Efficacy of Entresto, PARADIGM-HF
Table 23: Safety of Entresto, PARADIGM-HF
Table 24: Entresto SWOT Analysis, 2016
Table 25: Summary of major clinical trials assessing the efficacy of beta blockers in HF-REF patients.
Table 26: Product Profile - Procoralan
Table 27: Efficacy of Procoralan, SHIFT study
Table 28: Procoralan SWOT Analysis, 2016
Table 29: Unmet Need and Opportunity in HF, 2016
Table 30: Product Profile - Omecamtiv Mecarbil
Table 31: Efficacy of Omecamtiv Mecarbil, COSMIC-HF
Table 32: Omecamtiv Mecarbil SWOT Analysis, 2016
Table 33: Product Profile - Vericiguat
Table 34: Efficacy of Vericiguat, SOCRATES-Reduced
Table 35: Safety of Vericiguat, SOCRATES-Reduced
Table 36: Vericiguat SWOT Analysis, 2016
Table 37: Product Profile - RT-100
Table 38: RT-100 SWOT Analysis, 2016
Table 39: Product Profile - CXL-1427
Table 40: CXL-1427 SWOT Analysis, 2016
Table 41: Drugs in Development for Heart Failure, 2016
Table 42: Key Companies in the Heart Failure Market in the 7MM, 2016
Table 43: Amgen’s HF Portfolio Assessment, 2016
Table 44: Bayer’s HF Portfolio Assessment, 2016
Table 45: Bristol-Myers Squibb HF Portfolio Assessment, 2016
Table 46: Servier’s HF Portfolio Assessment, 2016
Table 47: Novartis’ Disease Portfolio Assessment, 2016
Table 48: Renova Therapeutics’ Disease Portfolio Assessment, 2016
Table 49: Heart Failure Market - Global Drivers and Barriers, 2016-2026
Table 50: Key Events Impacting Sales for HF in the US, 2016-2026
Table 51: HF Market - Global Drivers and Barriers in the US, 2016-2026
Table 52: Key Events Impacting Sales for Heart Failure in the 5EU, 2016-2026
Table 53: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2016-2026
Table 54: Key Events Impacting Sales for Heart Failure in Japan, 2016-2026
Table 55: Heart Failure Market - Global Drivers and Barriers in Japan, 2016-2026
Table 56: Key Historical and Projected Launch Dates for HF
Table 57: Key Historical and Projected Patent Expiry Dates for Heart Failure
Table 58: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales for Heart Failure by Country, 2016 and 2026
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026
Figure 3: Changes in Cardiac Structure in HF
Figure 4: RAAS Mechanism of Action
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, Ages ≥45 Years, 2016
Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of CHF (%), Men and Women, Ages ≥45 Years, 2016
Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF
Figure 8: 7MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF
Figure 10: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by EF
Figure 11: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by Ventricular Dysfunction
Figure 12: 7MM, Sources Used to Forecast Hospitalizations for Acute HF
Figure 13: 7MM, Sources Used to Forecast Hospitalizations for Acute HF by Worsening CHF, Advanced HF, and de novo HF
Figure 14: 7MM, Sources Used to Forecast Hospital Length of Stay for Acute HF Hospitalization
Figure 15: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, 2016
Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2016
Figure 18: 7MM, Diagnosed Incident Cases of HF by EF, Both Sexes, Ages ≥45 Years, N, 2016
Figure 19: 7MM, Diagnosed Incident Cases of HF by VD, Both Sexes, Ages ≥45 Years, N, 2016
Figure 20: 7MM, Acute HF Hospitalizations, Both Sexes, Ages ≥45 Years, N, 2016 to 2026
Figure 21: 7MM, Acute HF Hospitalizations by Patients Admitted and Discharged, Both Sexes, Ages ≥45 Years, 2016
Figure 22: 7MM, Acute HF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, Ages ≥45 Years, 2016
Figure 23: 7MM, Hospital Length of Stay for Acute HF Hospitalization, Both Sexes, Ages ≥45 Years, N, 2016
Figure 24: 7MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016
Figure 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016
Figure 26: 7MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, Ages ≥45 Years, N, 2016
Figure 27: 7MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
Figure 28: 7MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
Figure 29: 7MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
Figure 30: Diagnostic Algorithm for Chronic HF
Figure 31: Diagnostic Algorithm for Acute HF
Figure 32: HF based on the ACCF/AHA staging system
Figure 33: Classification of acute HF patients
Figure 34: Management of acute HF patients
Figure 35: Heart Failure - Drugs in Development, 2016
Figure 36: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026
Figure 37: Company Portfolio Gap Analysis in Heart Failure, 2016-2026
Figure 38: Global Sales for Chronic HF by Country, 2016 and 2026
Figure 39: Global Sales for acute HF by Country, 2016 and 2026
Figure 40: Sales for Chronic HF by Drug Class in the US, 2016 and 2026
Figure 41: Sales for Chronic HF by Drug Class in the 5EU, 2016 and 2026
Figure 42: Sales for HF by Drug Class in Japan, 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report